Kirk N. Campbell, MD
C. Mahlon Kline Professor
Department: Medicine
Contact information
3400 Spruce Street
Philadelphia, PA 19104
Philadelphia, PA 19104
Education:
BS (Biochemistry--Magna cum laude)
City College of the City University of New York, New York, NY, 1996.
MD (Medicine)
University of Connecticut, Farmington, CT, 2000.
Permanent linkBS (Biochemistry--Magna cum laude)
City College of the City University of New York, New York, NY, 1996.
MD (Medicine)
University of Connecticut, Farmington, CT, 2000.
Description of Clinical Expertise
My clinical interest is in glomerular disease with a particular focus on IgA nephropathy and podocytopathies including focal segmental glomerulosclerosis (FSGS) and minimal change disease.Description of Research Expertise
Dr. Campbell leads an NIH-funded research program focused on podocyte cell biology, experimental glomerular disease and clinical trials in the rare kidney disease space. The projects center on advancing the understanding of the underlying mechanisms involved in glomerular disease progression while identifying targets for therapeutic intervention. The work has resulted in two patents and support from a Harrington Discovery Institute Scholar-Innovator Award, He has been a lead principal investigator, steering committee chair and data safety monitoring committee member for multiple clinical trials testing novel agents for FSGS, IgA nephropathy, lupus nephritis and membranous nephropathy. He is an elected member of the American Society for Clinical Investigation and a member of the Editorial Boards of Kidney360, Kidney International, American Journal of Kidney Disease, Frontiers in Medicine and the American Journal of Physiology – Renal Physiology.Selected Publications
Meliambro K, He JC, Campbell KN.: Podocyte-targeted therapies - progress and future directions. Nat Rev Nephrol 20(10): 643-658, Oct 2024.Cantarelli C, Campbell KN, Cravedi P.: Parietal epithelial cells in glomerulosclerosis: a new piece in the puzzle? J Nephrol Oct 1 2024 Notes: doi: 10.1007/s40620-024-02100-9. Online ahead of print.
de Cos M, Mosoyan G, Chauhan K, Troost JP, Wong JS, Lefferts S, Morgan P, Meliambro K, Egerman M, Ray J, Parker T, Levine D, Seshan S, Bardash Y, Horowitz B, Kent CA, Shaw MM, Perlman A, Moledina DG, Coca SG, Campbell KN.: Urinary Plasminogen as a Marker of Disease Progression in Human Glomerular Disease. Am J Kidney Dis 84(2): 205-214.e1, Aug 2024.
Li J, Wisnivesky JP, Lin JJ, Campbell KN, Hu L, Kale MS.: Examining the Trajectory of Health-Related Quality of Life among Coronavirus Disease Patients. J Gen Intern Med 39(10): 1820-1827, Aug 2024.
Suresh V, Stillman IE, Campbell KN, Meliambro K.: Focal Segmental Glomerulosclerosis. Adv Kidney Dis Health 31(4): 275-289, Jul 2024.
Jhaveri KD, Campbell KN, Gibson KL.: Nephrotic Syndrome: Have We Entered a New Era? Adv Kidney Dis Health 31(4): 265-266, Jul 2024.
Campbell KN, Gibson KL, Jhaveri KD.: Nephritic Syndromes: A Lot to Progress. Adv Kidney Dis Health 31(3): 167-169, May 2024.
Campbell KN, Gesualdo L, Murphy E, Rheault MN, Srivastava T, Tesar V, Komers R, Trachtman H.: Sparsentan for Focal Segmental Glomerulosclerosis in the DUET Open-Label Extension: Long-term Efficacy and Safety. Kidney Med 6(6): 100833, Apr 26 2024.
Campbell KN, Griffin S, Trachtman H, Geletka R, Wong MG.: Practical Considerations for the Use of Sparsentan in the Treatment of Patients with IgAN in Clinical Practice. Int J Nephrol Renovasc Dis 16: 281-291, Dec 2023.
Shilane D, Miller S, Fleming J, Bar J, Corbin Y, Garcia M, Gasner MR, Campbell KN, Brown S, Weber E.: Barriers to Telehealth Utilization Among Patients of Limited Income with Chronic Conditions and a Gap in Care. Telemed J E Health 29(11): 1659-1666, Nov 2023.